Leukemia & lymphoma · 2021
Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Dayu, Shi Hongxia, Liu Xiaoli, Duan Minghui, Zhuang Junling, Du Xin, Qin Ling, Hui Wuhan, Liang Rong, Wang Meifang, Chen Ye, Li Dongyun, Yang Wei, Tang Gusheng, Zhang Weihua, Kuang Xia, Su Wei, Han Yanqiu, Chen Limei, Xu Jihong, Liu Zhuogang, Huang Jian, Zhao Chunting, Tong Hongyan, Hu Jianda, Chen Chunyan, Chen Xiequn, Xiao Zhijian, Jiang Qian
Аннотация
We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.